Journal of Clinical Oncology

Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not

Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for <i>IDH</i> -Mutated AML?

Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial

PURPOSE To evaluate the efficacy and safety of the bispecific human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugate (ADC) TQB2102 in the neoadjuvant trea...

Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for <i>IDH</i> -Mutated AML?

Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

PURPOSE Consensus molecular subtypes (CMSs) of metastatic colorectal cancer (mCRC) are debatable biomarkers. An individual patient data (IPD) meta-analysis was performed to test fo...

Are You Bereaved?

Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard?

Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

PURPOSE For patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor ( EGFR...

Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study

PURPOSE Quizartinib, an oral, selective, second-generation, type-II FMS-like tyrosine kinase 3 (FLT3) inhibitor with high binding affinity to internal tandem...

Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial

PURPOSE We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC)....